Global Sleep Wake Disorder
Global Sleep Wake Disorder

Sleep Wake Disorder Comprehensive Study by Type (Insomnia (Short-Term Insomnia, Chronic Insomnia), Sleep Apnea, Narcolepsy, Restless Legs Syndrome, REM Sleep Behavior Disorder), Application (Hospitals, Clinics, Research Centers, Others), Treatment (Therapy (Cognitive behavioral therapy (CBT)) Players and Region - Global Market Outlook to 2024

Sleep Wake Disorder Market Segmented into XX Submarkets. | Forecast Years: 2019- 2024  

Feb 2020 Edition 227 Pages 174 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Scope of the Study

Sleep disorders include problems with the quality, timing and amount of sleep, which cause problems with functioning and suffering during the daytime. There are different types of sleep disorders, which are insomnia, narcolepsy, obstructive sleep apnea, and restless leg syndrome and among which insomnia is the most common. According to The American Psychiatric Association in primary care, approx. 10-20 percent of people complain of significant sleep problems and about one-third of adults are having insomnia symptoms and 6-10 percent meet the criteria for insomnia disorder. In America, more than 50 million people have chronic sleep disorders.

The market study is being classified by Type (Insomnia [Short-Term Insomnia, Chronic Insomnia], Sleep Apnea, Narcolepsy, Restless Legs Syndrome and REM Sleep Behavior Disorder), by Application (Hospitals, Clinics, Research Centers and Others) and major geographies with country level break-up.

Arena Pharmaceuticals (United States), Boehringer Ingelheim (Germany), Fabre-Kramer Pharmaceuticals (United States), Jazz Pharmaceuticals (Ireland), Merck & Co (United States), Glaxo Smith Kline (United Kingdom), Respirerx Pharmaceuticals (United States), Neurocrine Biosciences (United States), Koninklijke Philips N.V. (Netherlands), Medtronic PLC (Ireland), Teva Pharmaceutical Industries Ltd. (Israel) and Vanda Pharmaceuticals Inc. (United States) are some of the key players profiled in the study.

Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Sleep Wake Disorder market throughout the predicted period.

Segment Analysis
AdvanceMarketAnalytics has segmented the market of Global Sleep Wake Disorder market by Type, Application and Region.

On the basis of geography, the market of Sleep Wake Disorder has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Drivers
  • Increasing Incidence of Depression & Medical Disorder
  • Rising Geriatric Population Suffering From Sleep Disorder
  • High Usage of Sleep Apnea Devices and Growing Healthcare Facilities

Market Trend
  • Introduction of Home Sleep Test Kits and Wearable Monitors
  • Introduction of Continuous Positive Airway Pressure (CPAP) Therapy

Restraints
  • Side Effects Associated with the Drug used to Treat Sleep Wake Disorder

Opportunities
  • Rising Investment on Research and Development of Drugs for the Sleep Wake Disorder
  • Affordable Reimbursement Scenario for Drugs prescribed in Insomnia Treatment

Challenges
  • Patent Expiration of Sleep Disorder Treatment Drugs


Market Leaders and their expansionary development strategies
On January 16, 2020 - Merck completed the acquisition of ArQule through a merger of Merck’s wholly-owned subsidiary with and into ArQule.
On January 22, 2020 - Jazz Pharmaceuticals plc has announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration on January, 2020 seeking marketing approval for JZP-258, an investigational medicine for the treatment of cataplexy and excessive daytime sleepiness (EDS) in patients 7 years of age and older with narcolepsy.


Key Target Audience
Manufacturers of Sleep Disorder Drugs, Industry Associations, Potential Investors, Healthcare Industry, Regulatory Bodies and Governmental Bodies

Customization in the Report Available:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase
Report Objectives / Segmentation Covered
By Type
  • Insomnia [Short-Term Insomnia, Chronic Insomnia]
  • Sleep Apnea
  • Narcolepsy
  • Restless Legs Syndrome
  • REM Sleep Behavior Disorder
By Application
  • Hospitals
  • Clinics
  • Research Centers
  • Others
By Treatment
  • Therapy [Cognitive behavioral therapy (CBT)

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Incidence of Depression & Medical Disorder
      • 3.2.2. Rising Geriatric Population Suffering From Sleep Disorder
      • 3.2.3. High Usage of Sleep Apnea Devices and Growing Healthcare Facilities
    • 3.3. Market Challenges
      • 3.3.1. Patent Expiration of Sleep Disorder Treatment Drugs
    • 3.4. Market Trends
      • 3.4.1. Introduction of Home Sleep Test Kits and Wearable Monitors
      • 3.4.2. Introduction of Continuous Positive Airway Pressure (CPAP) Therapy
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Sleep Wake Disorder, by Type, Application, Treatment and Region (value) (2013-2018)
    • 5.1. Introduction
    • 5.2. Global Sleep Wake Disorder (Value)
      • 5.2.1. Global Sleep Wake Disorder by: Type (Value)
        • 5.2.1.1. Insomnia [Short-Term Insomnia, Chronic Insomnia]
        • 5.2.1.2. Sleep Apnea
        • 5.2.1.3. Narcolepsy
        • 5.2.1.4. Restless Legs Syndrome
        • 5.2.1.5. REM Sleep Behavior Disorder
      • 5.2.2. Global Sleep Wake Disorder by: Application (Value)
        • 5.2.2.1. Hospitals
        • 5.2.2.2. Clinics
        • 5.2.2.3. Research Centers
        • 5.2.2.4. Others
      • 5.2.3. Global Sleep Wake Disorder by: Treatment (Value)
        • 5.2.3.1. Therapy [Cognitive behavioral therapy (CBT)
      • 5.2.4. Global Sleep Wake Disorder Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Sleep Wake Disorder: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2018)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Arena Pharmaceuticals (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Boehringer Ingelheim (Germany)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Fabre-Kramer Pharmaceuticals (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Jazz Pharmaceuticals (Ireland)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Merck & Co (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Glaxo Smith Kline (United Kingdom)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Respirerx Pharmaceuticals (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Neurocrine Biosciences (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Koninklijke Philips N.V. (Netherlands)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Medtronic PLC (Ireland)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Teva Pharmaceutical Industries Ltd. (Israel)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
      • 6.4.12. Vanda Pharmaceuticals Inc. (United States)
        • 6.4.12.1. Business Overview
        • 6.4.12.2. Products/Services Offerings
        • 6.4.12.3. Financial Analysis
        • 6.4.12.4. SWOT Analysis
  • 7. Global Sleep Wake Disorder Sale, by Type, Application, Treatment and Region (value) (2019-2024)
    • 7.1. Introduction
    • 7.2. Global Sleep Wake Disorder (Value)
      • 7.2.1. Global Sleep Wake Disorder by: Type (Value)
        • 7.2.1.1. Insomnia [Short-Term Insomnia, Chronic Insomnia]
        • 7.2.1.2. Sleep Apnea
        • 7.2.1.3. Narcolepsy
        • 7.2.1.4. Restless Legs Syndrome
        • 7.2.1.5. REM Sleep Behavior Disorder
      • 7.2.2. Global Sleep Wake Disorder by: Application (Value)
        • 7.2.2.1. Hospitals
        • 7.2.2.2. Clinics
        • 7.2.2.3. Research Centers
        • 7.2.2.4. Others
      • 7.2.3. Global Sleep Wake Disorder by: Treatment (Value)
        • 7.2.3.1. Therapy [Cognitive behavioral therapy (CBT)
      • 7.2.4. Global Sleep Wake Disorder Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Sleep Wake Disorder: by Type(USD Million)
  • Table 2. Sleep Wake Disorder Insomnia [Short-Term Insomnia, Chronic Insomnia] , by Region USD Million (2013-2018)
  • Table 3. Sleep Wake Disorder Sleep Apnea , by Region USD Million (2013-2018)
  • Table 4. Sleep Wake Disorder Narcolepsy , by Region USD Million (2013-2018)
  • Table 5. Sleep Wake Disorder Restless Legs Syndrome , by Region USD Million (2013-2018)
  • Table 6. Sleep Wake Disorder REM Sleep Behavior Disorder , by Region USD Million (2013-2018)
  • Table 7. Sleep Wake Disorder: by Application(USD Million)
  • Table 8. Sleep Wake Disorder Hospitals , by Region USD Million (2013-2018)
  • Table 9. Sleep Wake Disorder Clinics , by Region USD Million (2013-2018)
  • Table 10. Sleep Wake Disorder Research Centers , by Region USD Million (2013-2018)
  • Table 11. Sleep Wake Disorder Others , by Region USD Million (2013-2018)
  • Table 12. Sleep Wake Disorder: by Treatment(USD Million)
  • Table 13. Sleep Wake Disorder Therapy [Cognitive behavioral therapy (CBT) , by Region USD Million (2013-2018)
  • Table 14. South America Sleep Wake Disorder, by Country USD Million (2013-2018)
  • Table 15. South America Sleep Wake Disorder, by Type USD Million (2013-2018)
  • Table 16. South America Sleep Wake Disorder, by Application USD Million (2013-2018)
  • Table 17. South America Sleep Wake Disorder, by Treatment USD Million (2013-2018)
  • Table 18. Brazil Sleep Wake Disorder, by Type USD Million (2013-2018)
  • Table 19. Brazil Sleep Wake Disorder, by Application USD Million (2013-2018)
  • Table 20. Brazil Sleep Wake Disorder, by Treatment USD Million (2013-2018)
  • Table 21. Argentina Sleep Wake Disorder, by Type USD Million (2013-2018)
  • Table 22. Argentina Sleep Wake Disorder, by Application USD Million (2013-2018)
  • Table 23. Argentina Sleep Wake Disorder, by Treatment USD Million (2013-2018)
  • Table 24. Rest of South America Sleep Wake Disorder, by Type USD Million (2013-2018)
  • Table 25. Rest of South America Sleep Wake Disorder, by Application USD Million (2013-2018)
  • Table 26. Rest of South America Sleep Wake Disorder, by Treatment USD Million (2013-2018)
  • Table 27. Asia Pacific Sleep Wake Disorder, by Country USD Million (2013-2018)
  • Table 28. Asia Pacific Sleep Wake Disorder, by Type USD Million (2013-2018)
  • Table 29. Asia Pacific Sleep Wake Disorder, by Application USD Million (2013-2018)
  • Table 30. Asia Pacific Sleep Wake Disorder, by Treatment USD Million (2013-2018)
  • Table 31. China Sleep Wake Disorder, by Type USD Million (2013-2018)
  • Table 32. China Sleep Wake Disorder, by Application USD Million (2013-2018)
  • Table 33. China Sleep Wake Disorder, by Treatment USD Million (2013-2018)
  • Table 34. Japan Sleep Wake Disorder, by Type USD Million (2013-2018)
  • Table 35. Japan Sleep Wake Disorder, by Application USD Million (2013-2018)
  • Table 36. Japan Sleep Wake Disorder, by Treatment USD Million (2013-2018)
  • Table 37. India Sleep Wake Disorder, by Type USD Million (2013-2018)
  • Table 38. India Sleep Wake Disorder, by Application USD Million (2013-2018)
  • Table 39. India Sleep Wake Disorder, by Treatment USD Million (2013-2018)
  • Table 40. South Korea Sleep Wake Disorder, by Type USD Million (2013-2018)
  • Table 41. South Korea Sleep Wake Disorder, by Application USD Million (2013-2018)
  • Table 42. South Korea Sleep Wake Disorder, by Treatment USD Million (2013-2018)
  • Table 43. Taiwan Sleep Wake Disorder, by Type USD Million (2013-2018)
  • Table 44. Taiwan Sleep Wake Disorder, by Application USD Million (2013-2018)
  • Table 45. Taiwan Sleep Wake Disorder, by Treatment USD Million (2013-2018)
  • Table 46. Australia Sleep Wake Disorder, by Type USD Million (2013-2018)
  • Table 47. Australia Sleep Wake Disorder, by Application USD Million (2013-2018)
  • Table 48. Australia Sleep Wake Disorder, by Treatment USD Million (2013-2018)
  • Table 49. Rest of Asia-Pacific Sleep Wake Disorder, by Type USD Million (2013-2018)
  • Table 50. Rest of Asia-Pacific Sleep Wake Disorder, by Application USD Million (2013-2018)
  • Table 51. Rest of Asia-Pacific Sleep Wake Disorder, by Treatment USD Million (2013-2018)
  • Table 52. Europe Sleep Wake Disorder, by Country USD Million (2013-2018)
  • Table 53. Europe Sleep Wake Disorder, by Type USD Million (2013-2018)
  • Table 54. Europe Sleep Wake Disorder, by Application USD Million (2013-2018)
  • Table 55. Europe Sleep Wake Disorder, by Treatment USD Million (2013-2018)
  • Table 56. Germany Sleep Wake Disorder, by Type USD Million (2013-2018)
  • Table 57. Germany Sleep Wake Disorder, by Application USD Million (2013-2018)
  • Table 58. Germany Sleep Wake Disorder, by Treatment USD Million (2013-2018)
  • Table 59. France Sleep Wake Disorder, by Type USD Million (2013-2018)
  • Table 60. France Sleep Wake Disorder, by Application USD Million (2013-2018)
  • Table 61. France Sleep Wake Disorder, by Treatment USD Million (2013-2018)
  • Table 62. Italy Sleep Wake Disorder, by Type USD Million (2013-2018)
  • Table 63. Italy Sleep Wake Disorder, by Application USD Million (2013-2018)
  • Table 64. Italy Sleep Wake Disorder, by Treatment USD Million (2013-2018)
  • Table 65. United Kingdom Sleep Wake Disorder, by Type USD Million (2013-2018)
  • Table 66. United Kingdom Sleep Wake Disorder, by Application USD Million (2013-2018)
  • Table 67. United Kingdom Sleep Wake Disorder, by Treatment USD Million (2013-2018)
  • Table 68. Netherlands Sleep Wake Disorder, by Type USD Million (2013-2018)
  • Table 69. Netherlands Sleep Wake Disorder, by Application USD Million (2013-2018)
  • Table 70. Netherlands Sleep Wake Disorder, by Treatment USD Million (2013-2018)
  • Table 71. Rest of Europe Sleep Wake Disorder, by Type USD Million (2013-2018)
  • Table 72. Rest of Europe Sleep Wake Disorder, by Application USD Million (2013-2018)
  • Table 73. Rest of Europe Sleep Wake Disorder, by Treatment USD Million (2013-2018)
  • Table 74. MEA Sleep Wake Disorder, by Country USD Million (2013-2018)
  • Table 75. MEA Sleep Wake Disorder, by Type USD Million (2013-2018)
  • Table 76. MEA Sleep Wake Disorder, by Application USD Million (2013-2018)
  • Table 77. MEA Sleep Wake Disorder, by Treatment USD Million (2013-2018)
  • Table 78. Middle East Sleep Wake Disorder, by Type USD Million (2013-2018)
  • Table 79. Middle East Sleep Wake Disorder, by Application USD Million (2013-2018)
  • Table 80. Middle East Sleep Wake Disorder, by Treatment USD Million (2013-2018)
  • Table 81. Africa Sleep Wake Disorder, by Type USD Million (2013-2018)
  • Table 82. Africa Sleep Wake Disorder, by Application USD Million (2013-2018)
  • Table 83. Africa Sleep Wake Disorder, by Treatment USD Million (2013-2018)
  • Table 84. North America Sleep Wake Disorder, by Country USD Million (2013-2018)
  • Table 85. North America Sleep Wake Disorder, by Type USD Million (2013-2018)
  • Table 86. North America Sleep Wake Disorder, by Application USD Million (2013-2018)
  • Table 87. North America Sleep Wake Disorder, by Treatment USD Million (2013-2018)
  • Table 88. United States Sleep Wake Disorder, by Type USD Million (2013-2018)
  • Table 89. United States Sleep Wake Disorder, by Application USD Million (2013-2018)
  • Table 90. United States Sleep Wake Disorder, by Treatment USD Million (2013-2018)
  • Table 91. Canada Sleep Wake Disorder, by Type USD Million (2013-2018)
  • Table 92. Canada Sleep Wake Disorder, by Application USD Million (2013-2018)
  • Table 93. Canada Sleep Wake Disorder, by Treatment USD Million (2013-2018)
  • Table 94. Mexico Sleep Wake Disorder, by Type USD Million (2013-2018)
  • Table 95. Mexico Sleep Wake Disorder, by Application USD Million (2013-2018)
  • Table 96. Mexico Sleep Wake Disorder, by Treatment USD Million (2013-2018)
  • Table 97. Company Basic Information, Sales Area and Its Competitors
  • Table 98. Company Basic Information, Sales Area and Its Competitors
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Company Basic Information, Sales Area and Its Competitors
  • Table 108. Company Basic Information, Sales Area and Its Competitors
  • Table 109. Sleep Wake Disorder: by Type(USD Million)
  • Table 110. Sleep Wake Disorder Insomnia [Short-Term Insomnia, Chronic Insomnia] , by Region USD Million (2019-2024)
  • Table 111. Sleep Wake Disorder Sleep Apnea , by Region USD Million (2019-2024)
  • Table 112. Sleep Wake Disorder Narcolepsy , by Region USD Million (2019-2024)
  • Table 113. Sleep Wake Disorder Restless Legs Syndrome , by Region USD Million (2019-2024)
  • Table 114. Sleep Wake Disorder REM Sleep Behavior Disorder , by Region USD Million (2019-2024)
  • Table 115. Sleep Wake Disorder: by Application(USD Million)
  • Table 116. Sleep Wake Disorder Hospitals , by Region USD Million (2019-2024)
  • Table 117. Sleep Wake Disorder Clinics , by Region USD Million (2019-2024)
  • Table 118. Sleep Wake Disorder Research Centers , by Region USD Million (2019-2024)
  • Table 119. Sleep Wake Disorder Others , by Region USD Million (2019-2024)
  • Table 120. Sleep Wake Disorder: by Treatment(USD Million)
  • Table 121. Sleep Wake Disorder Therapy [Cognitive behavioral therapy (CBT) , by Region USD Million (2019-2024)
  • Table 122. South America Sleep Wake Disorder, by Country USD Million (2019-2024)
  • Table 123. South America Sleep Wake Disorder, by Type USD Million (2019-2024)
  • Table 124. South America Sleep Wake Disorder, by Application USD Million (2019-2024)
  • Table 125. South America Sleep Wake Disorder, by Treatment USD Million (2019-2024)
  • Table 126. Brazil Sleep Wake Disorder, by Type USD Million (2019-2024)
  • Table 127. Brazil Sleep Wake Disorder, by Application USD Million (2019-2024)
  • Table 128. Brazil Sleep Wake Disorder, by Treatment USD Million (2019-2024)
  • Table 129. Argentina Sleep Wake Disorder, by Type USD Million (2019-2024)
  • Table 130. Argentina Sleep Wake Disorder, by Application USD Million (2019-2024)
  • Table 131. Argentina Sleep Wake Disorder, by Treatment USD Million (2019-2024)
  • Table 132. Rest of South America Sleep Wake Disorder, by Type USD Million (2019-2024)
  • Table 133. Rest of South America Sleep Wake Disorder, by Application USD Million (2019-2024)
  • Table 134. Rest of South America Sleep Wake Disorder, by Treatment USD Million (2019-2024)
  • Table 135. Asia Pacific Sleep Wake Disorder, by Country USD Million (2019-2024)
  • Table 136. Asia Pacific Sleep Wake Disorder, by Type USD Million (2019-2024)
  • Table 137. Asia Pacific Sleep Wake Disorder, by Application USD Million (2019-2024)
  • Table 138. Asia Pacific Sleep Wake Disorder, by Treatment USD Million (2019-2024)
  • Table 139. China Sleep Wake Disorder, by Type USD Million (2019-2024)
  • Table 140. China Sleep Wake Disorder, by Application USD Million (2019-2024)
  • Table 141. China Sleep Wake Disorder, by Treatment USD Million (2019-2024)
  • Table 142. Japan Sleep Wake Disorder, by Type USD Million (2019-2024)
  • Table 143. Japan Sleep Wake Disorder, by Application USD Million (2019-2024)
  • Table 144. Japan Sleep Wake Disorder, by Treatment USD Million (2019-2024)
  • Table 145. India Sleep Wake Disorder, by Type USD Million (2019-2024)
  • Table 146. India Sleep Wake Disorder, by Application USD Million (2019-2024)
  • Table 147. India Sleep Wake Disorder, by Treatment USD Million (2019-2024)
  • Table 148. South Korea Sleep Wake Disorder, by Type USD Million (2019-2024)
  • Table 149. South Korea Sleep Wake Disorder, by Application USD Million (2019-2024)
  • Table 150. South Korea Sleep Wake Disorder, by Treatment USD Million (2019-2024)
  • Table 151. Taiwan Sleep Wake Disorder, by Type USD Million (2019-2024)
  • Table 152. Taiwan Sleep Wake Disorder, by Application USD Million (2019-2024)
  • Table 153. Taiwan Sleep Wake Disorder, by Treatment USD Million (2019-2024)
  • Table 154. Australia Sleep Wake Disorder, by Type USD Million (2019-2024)
  • Table 155. Australia Sleep Wake Disorder, by Application USD Million (2019-2024)
  • Table 156. Australia Sleep Wake Disorder, by Treatment USD Million (2019-2024)
  • Table 157. Rest of Asia-Pacific Sleep Wake Disorder, by Type USD Million (2019-2024)
  • Table 158. Rest of Asia-Pacific Sleep Wake Disorder, by Application USD Million (2019-2024)
  • Table 159. Rest of Asia-Pacific Sleep Wake Disorder, by Treatment USD Million (2019-2024)
  • Table 160. Europe Sleep Wake Disorder, by Country USD Million (2019-2024)
  • Table 161. Europe Sleep Wake Disorder, by Type USD Million (2019-2024)
  • Table 162. Europe Sleep Wake Disorder, by Application USD Million (2019-2024)
  • Table 163. Europe Sleep Wake Disorder, by Treatment USD Million (2019-2024)
  • Table 164. Germany Sleep Wake Disorder, by Type USD Million (2019-2024)
  • Table 165. Germany Sleep Wake Disorder, by Application USD Million (2019-2024)
  • Table 166. Germany Sleep Wake Disorder, by Treatment USD Million (2019-2024)
  • Table 167. France Sleep Wake Disorder, by Type USD Million (2019-2024)
  • Table 168. France Sleep Wake Disorder, by Application USD Million (2019-2024)
  • Table 169. France Sleep Wake Disorder, by Treatment USD Million (2019-2024)
  • Table 170. Italy Sleep Wake Disorder, by Type USD Million (2019-2024)
  • Table 171. Italy Sleep Wake Disorder, by Application USD Million (2019-2024)
  • Table 172. Italy Sleep Wake Disorder, by Treatment USD Million (2019-2024)
  • Table 173. United Kingdom Sleep Wake Disorder, by Type USD Million (2019-2024)
  • Table 174. United Kingdom Sleep Wake Disorder, by Application USD Million (2019-2024)
  • Table 175. United Kingdom Sleep Wake Disorder, by Treatment USD Million (2019-2024)
  • Table 176. Netherlands Sleep Wake Disorder, by Type USD Million (2019-2024)
  • Table 177. Netherlands Sleep Wake Disorder, by Application USD Million (2019-2024)
  • Table 178. Netherlands Sleep Wake Disorder, by Treatment USD Million (2019-2024)
  • Table 179. Rest of Europe Sleep Wake Disorder, by Type USD Million (2019-2024)
  • Table 180. Rest of Europe Sleep Wake Disorder, by Application USD Million (2019-2024)
  • Table 181. Rest of Europe Sleep Wake Disorder, by Treatment USD Million (2019-2024)
  • Table 182. MEA Sleep Wake Disorder, by Country USD Million (2019-2024)
  • Table 183. MEA Sleep Wake Disorder, by Type USD Million (2019-2024)
  • Table 184. MEA Sleep Wake Disorder, by Application USD Million (2019-2024)
  • Table 185. MEA Sleep Wake Disorder, by Treatment USD Million (2019-2024)
  • Table 186. Middle East Sleep Wake Disorder, by Type USD Million (2019-2024)
  • Table 187. Middle East Sleep Wake Disorder, by Application USD Million (2019-2024)
  • Table 188. Middle East Sleep Wake Disorder, by Treatment USD Million (2019-2024)
  • Table 189. Africa Sleep Wake Disorder, by Type USD Million (2019-2024)
  • Table 190. Africa Sleep Wake Disorder, by Application USD Million (2019-2024)
  • Table 191. Africa Sleep Wake Disorder, by Treatment USD Million (2019-2024)
  • Table 192. North America Sleep Wake Disorder, by Country USD Million (2019-2024)
  • Table 193. North America Sleep Wake Disorder, by Type USD Million (2019-2024)
  • Table 194. North America Sleep Wake Disorder, by Application USD Million (2019-2024)
  • Table 195. North America Sleep Wake Disorder, by Treatment USD Million (2019-2024)
  • Table 196. United States Sleep Wake Disorder, by Type USD Million (2019-2024)
  • Table 197. United States Sleep Wake Disorder, by Application USD Million (2019-2024)
  • Table 198. United States Sleep Wake Disorder, by Treatment USD Million (2019-2024)
  • Table 199. Canada Sleep Wake Disorder, by Type USD Million (2019-2024)
  • Table 200. Canada Sleep Wake Disorder, by Application USD Million (2019-2024)
  • Table 201. Canada Sleep Wake Disorder, by Treatment USD Million (2019-2024)
  • Table 202. Mexico Sleep Wake Disorder, by Type USD Million (2019-2024)
  • Table 203. Mexico Sleep Wake Disorder, by Application USD Million (2019-2024)
  • Table 204. Mexico Sleep Wake Disorder, by Treatment USD Million (2019-2024)
  • Table 205. Research Programs/Design for This Report
  • Table 206. Key Data Information from Secondary Sources
  • Table 207. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Sleep Wake Disorder: by Type USD Million (2013-2018)
  • Figure 5. Global Sleep Wake Disorder: by Application USD Million (2013-2018)
  • Figure 6. Global Sleep Wake Disorder: by Treatment USD Million (2013-2018)
  • Figure 7. South America Sleep Wake Disorder Share (%), by Country
  • Figure 8. Asia Pacific Sleep Wake Disorder Share (%), by Country
  • Figure 9. Europe Sleep Wake Disorder Share (%), by Country
  • Figure 10. MEA Sleep Wake Disorder Share (%), by Country
  • Figure 11. North America Sleep Wake Disorder Share (%), by Country
  • Figure 12. Global Sleep Wake Disorder share by Players 2018 (%)
  • Figure 13. Global Sleep Wake Disorder share by Players (Top 3) 2018(%)
  • Figure 14. Global Sleep Wake Disorder share by Players (Top 5) 2018(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Arena Pharmaceuticals (United States) Revenue, Net Income and Gross profit
  • Figure 17. Arena Pharmaceuticals (United States) Revenue: by Geography 2018
  • Figure 18. Boehringer Ingelheim (Germany) Revenue, Net Income and Gross profit
  • Figure 19. Boehringer Ingelheim (Germany) Revenue: by Geography 2018
  • Figure 20. Fabre-Kramer Pharmaceuticals (United States) Revenue, Net Income and Gross profit
  • Figure 21. Fabre-Kramer Pharmaceuticals (United States) Revenue: by Geography 2018
  • Figure 22. Jazz Pharmaceuticals (Ireland) Revenue, Net Income and Gross profit
  • Figure 23. Jazz Pharmaceuticals (Ireland) Revenue: by Geography 2018
  • Figure 24. Merck & Co (United States) Revenue, Net Income and Gross profit
  • Figure 25. Merck & Co (United States) Revenue: by Geography 2018
  • Figure 26. Glaxo Smith Kline (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 27. Glaxo Smith Kline (United Kingdom) Revenue: by Geography 2018
  • Figure 28. Respirerx Pharmaceuticals (United States) Revenue, Net Income and Gross profit
  • Figure 29. Respirerx Pharmaceuticals (United States) Revenue: by Geography 2018
  • Figure 30. Neurocrine Biosciences (United States) Revenue, Net Income and Gross profit
  • Figure 31. Neurocrine Biosciences (United States) Revenue: by Geography 2018
  • Figure 32. Koninklijke Philips N.V. (Netherlands) Revenue, Net Income and Gross profit
  • Figure 33. Koninklijke Philips N.V. (Netherlands) Revenue: by Geography 2018
  • Figure 34. Medtronic PLC (Ireland) Revenue, Net Income and Gross profit
  • Figure 35. Medtronic PLC (Ireland) Revenue: by Geography 2018
  • Figure 36. Teva Pharmaceutical Industries Ltd. (Israel) Revenue, Net Income and Gross profit
  • Figure 37. Teva Pharmaceutical Industries Ltd. (Israel) Revenue: by Geography 2018
  • Figure 38. Vanda Pharmaceuticals Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 39. Vanda Pharmaceuticals Inc. (United States) Revenue: by Geography 2018
  • Figure 40. Global Sleep Wake Disorder: by Type USD Million (2019-2024)
  • Figure 41. Global Sleep Wake Disorder: by Application USD Million (2019-2024)
  • Figure 42. Global Sleep Wake Disorder: by Treatment USD Million (2019-2024)
  • Figure 43. South America Sleep Wake Disorder Share (%), by Country
  • Figure 44. Asia Pacific Sleep Wake Disorder Share (%), by Country
  • Figure 45. Europe Sleep Wake Disorder Share (%), by Country
  • Figure 46. MEA Sleep Wake Disorder Share (%), by Country
  • Figure 47. North America Sleep Wake Disorder Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • Arena Pharmaceuticals (United States)
  • Boehringer Ingelheim (Germany)
  • Fabre-Kramer Pharmaceuticals (United States)
  • Jazz Pharmaceuticals (Ireland)
  • Merck & Co (United States)
  • Glaxo Smith Kline (United Kingdom)
  • Respirerx Pharmaceuticals (United States)
  • Neurocrine Biosciences (United States)
  • Koninklijke Philips N.V. (Netherlands)
  • Medtronic PLC (Ireland)
  • Teva Pharmaceutical Industries Ltd. (Israel)
  • Vanda Pharmaceuticals Inc. (United States)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation